Technology Bundle ID
TAB-778

Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease

Applications
Therapeutics
Linked ID
E-208-2003-0
Lead Inventors
Stewart Levine (NHLBI)
Development Status
  • Early-stage
  • In vitro data available
Therapeutic Areas
Immunology
ICs
NHLBI
Tumor Necrosis Factor alpha (TNF-alpha) is a multifunctional cytokine that mediates inflammation, immune regulation, and cellular proliferation. This cytokine is converted to its active form by TNF-alpha converting enzyme (TACE). Pathological increases in TNF-alpha activity have been associated with a wide variety of inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer. Inhibiting the conversion of TNF-alpha to its active form by inhibiting TACE represents a potential treatment for these diseases.

The current technology provides peptides, derived from an N-terminal fragment of the TACE protein, that inhibit TACE activity. Also described are methods of using these peptides to lower levels of active TNF-alpha. These peptides could be used as a treatment for TNF-alpha-mediated inflammatory diseases.
Commercial Applications
Treatment of TNF-alpha mediated inflammatory diseases.
Competitive Advantages
Inhibition of TACE activity represents a novel mechanism to treat inflammatory disease.

Request More Info

Licensing Contact: